Association Between Pococyturia and Pre-eclampsia Severity

Overview

Pre-eclampsia is an hypertensive disorder appearing during pregnancy, inducing serious maternal, fetal and neonatal mortality and morbidity. Twenty four hours proteinuria is a key element to define pre-eclampsia severity but is delaying the result by 24 hours and constraining for the patient. A simple and rapid indicator for severe preeclampsia would help clinicians to make appropriate decision in patient management. We hypothesized that urinary podocyturia is correlated to preeclampsia severity. This is a prospective, non-interventional, monocentric study.

Full Title of Study: “Prospective Study : Association Between Pococyturia and Pre-eclampsia Severity”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 22, 2025

Interventions

  • Other: Dosage of urinary podocyturia
    • Dosage of urinary podocyturia at admission, delivery and post-partum visit

Arms, Groups and Cohorts

  • Pre-eclampsia
    • Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant

Clinical Trial Outcome Measures

Primary Measures

  • Severity of pre-eclampsia
    • Time Frame: at childbirth (maximum 10 months)
    • Severe preeclampsia is defined by preeclampsia with at least one of the following criteria : severe hypertension (PAS ≥ 160 mmHg et/ou PAD ≥ 110 mmHg) Renal impairment with: oliguria <500 ml / 24h or creatinine> 135 μmol / L or proteinuria> 5 g/d acute lung edema or persistent epigastric bar or HELLP syndrome eclampsia or rebellious neurological disorders (visual disturbances, polykinetic ROT, headache), thrombocytopenia <100 G / L Retro Placental Hematoma (HRP) or fetal repercussion.

Participating in This Clinical Trial

Inclusion Criteria

  • women aged 18 years or more – single pregnancy – admission for pre-eclampsia – patient receiving information and non-opposition to participate Exclusion Criteria:

  • multiple pregnancy – in utero fetal demise excepted if associated with pre-eclampsia – antecedent of nephropathy – fetal malformation, chromosomal anomalies – inability to understand information provided – prisoner or under administrative supervision

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Muriel DORET-DION, MD, 04 27 85 51 70, muriel.doret-dion@chu-lyon.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.